ABBV vs LLY
AbbVie Inc. vs Eli Lilly and Company · Healthcare · scored 2026-08-04
Head-to-head
The numbers that matter, side by side. A star marks the stronger stock on each merit measure.
| Measure | ABBV | LLY | |
|---|---|---|---|
| Gem Score | 59/100 ★ | 54/100 | |
| Strategies agreeing | 4 | 5 | |
| Price | $245.10 | $1,121.36 | |
| Market cap | $433B | $1000B | |
| Market regime | Bullish | Bullish | |
| Best-fit thesis | CAN SLIM | CAN SLIM |
Modeled from the GemStox stochastic + volatility models (order: ABBV · LLY). Not financial advice.
Strategy-thesis head-to-head
GemStox scores each stock across 14 independent investment theses. Here is where they differ.
| Strategy thesis | ABBV | LLY | Δ |
|---|---|---|---|
| GARP | ★ | +20 | |
| Mean Reversion | ★ | -24 | |
| Quality Compounder | ★ | -11 | |
| CAN SLIM | ★ | -2 | |
| Low-Vol Defensive | +0 | ||
| Catalyst / Event | +0 | ||
| Dividend Growth | +0 | ||
| S-Curve Growth | ★ | -8 | |
| Piotroski F-Score | ★ | -22 | |
| Operating Leverage | +0 | ||
| Net Payout Yield | ★ | +20 |
ABBV leads 2, LLY leads 5, 4 tied — of 11 comparable theses
Dimension by dimension
Average sub-signal score across valuation, quality, risk, growth, and momentum.
| Dimension | ABBV | LLY |
|---|---|---|
| Valuation | ★ | |
| Quality | ★ | |
| Risk | ★ | |
| Growth | ★ | |
| Momentum & Technicals | ★ |
How this comparison is computed
Every figure is computed from the same cached market + fundamentals data GemStox uses to score individual stocks — no two theses double-count. Try the free Stock Score calculator, read the full scoring methodology, or open either single-stock analysis above for the full 14-signal breakdown.
Want the full live comparison, not just the consensus?
The GemStox app's interactive Compare runs the live signal stack on any two tickers — probability scores, optimal position size, and pre-calculated stop/target levels. The public page above is the free, always-crawlable summary.
Unlock with the $3 Day Pass →Educational comparison generated from cached market + fundamentals data as of 2026-08-04. Not investment advice. Past performance does not guarantee future results.